Compare Amylx Pharmaceuticals Inc (AMLX) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Kohl's Corporation trades at $16.8 (market cap $1.91B). The key difference: Amylx Pharmaceuticals Inc and Kohl's Corporation are close in size by market cap, and Kohl's Corporation pays a 2.98% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KSS | |
|---|---|---|
Market Cap | $1.98B | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $24.71 |
52-Week Low | $7.64 | $9.27 |
Enterprise Value | $1.70B | $8.01B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Kohl's (KSS) trades at $16.80, up 3.0% today, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten expectations, with Q1 2026 showing early turnaround progress, but revenue has declined from $19.4B in 2022 to $16.2B in 2025. The stock is undervalued with a P/E of 7.06 and P/B of 0.47, while analyst sentiment is cautious with a consensus price target of $16.75.
The outlook hinges on Kohl's ability to stabilize sales through proprietary brands and cost controls, but risks include persistent revenue declines and competitive pressures. Upside potential exists if turnaround efforts gain traction, yet investor caution is warranted given weak technicals and mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
